Fulltext

Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning

Jäger, Dirk ; Taverna, Christian ; Zippelius, Alfred ; Knuth, Alexander

In: Cancer Immunology, Immunotherapy, 2004, vol. 53, no. 3, p. 144-147

Zum persönliche Liste hinzufügen
    Titel
    • Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning
    Autor
    • Jäger, Dirk. Klinik und Poliklinik für Onkologie, Universitätsspital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland
    • Taverna, Christian. Klinik und Poliklinik für Onkologie, Universitätsspital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland
    • Zippelius, Alfred. Klinik und Poliklinik für Onkologie, Universitätsspital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland
    • Knuth, Alexander. Klinik und Poliklinik für Onkologie, Universitätsspital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Cancer Immunology, Immunotherapy, 2004, vol. 53, no. 3, p. 144-147. Springer-Verlag
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:309998
    Summary
    The presence of tumor infiltrating T cells has been shown to be associated with a favorable prognosis in different tumor types. Several strategies have been developed to identify relevant tumor antigens which can be used for active immunotherapy strategies. The SEREX technique (serological analysis of cDNA expression libraries) identifies tumor antigens based on a spontaneous humoral immune response in cancer patients. This technique is not limited to tumor types that can be grown in cell culture or depends on established T cell clones recognizing the autologous tumor. Several steps of analysis are mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy: expression analysis; serological analysis with sera from tumor patients and normal individuals; identification of potential peptide epitopes for CD8 T cells and evaluation in T cell assays. This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1